CD73 inhibitors
Described herein are CD73 inhibitors and pharmaceutical compositions comprising said compounds. The subject compounds and compositions are useful for the treatment of cancer, infections, and neurodegenerative diseases.
1. A method of treating cancer in a subject, wherein the cancer is leukemia, lymphoma, or multiple myeloma, comprising administering to the subject a compound, selected from the group consisting of:
or a pharmaceutically acceptable salt thereof.
2. The method of claim 1 , wherein the compound is
or a pharmaceutically acceptable salt thereof.
3. The method of claim 1 , wherein the compound is
or a pharmaceutically acceptable salt thereof.
4. The method of claim 1 , wherein the compound is
or a pharmaceutically acceptable salt thereof.
5. The method of claim 1 , wherein the compound is
or a pharmaceutically acceptable salt thereof.
6. The method of claim 1 , wherein the compound is
or a pharmaceutically acceptable salt thereof.
7. The method of claim 1 , wherein the compound is
or a pharmaceutically acceptable salt thereof.
8. The method of claim 1 , wherein the compound is
or a pharmaceutically acceptable salt thereof.
9. The method of claim 1 , wherein the compound is
or a pharmaceutically acceptable salt thereof.
10. The method of claim 1 , wherein the compound is
or a pharmaceutically acceptable salt thereof.
11. The method of claim 1 , wherein the compound is
or a pharmaceutically acceptable salt thereof.
12. The method of claim 1 , wherein the compound is
or a pharmaceutically acceptable salt thereof.
13. The method of claim 1 , wherein the compound is
or a pharmaceutically acceptable salt thereof.
14. The method of claim 1 , wherein the cancer is leukemia.
15. The method of claim 14 , wherein the leukemia is acute lymphocytic leukemia, chronic lymphocytic leukemia, myelocytic leukemia, refractory anemia, preleukemia, chronic myelomonocytic leukemia (CMML), or hairy cell leukemia.
16. The method of claim 1 , wherein the cancer is lymphoma.
17. The method of claim 16 , wherein the lymphoma is Hodgkin's lymphoma or non-Hodgkin's lymphoma.
18. The method of claim 1 , wherein the cancer is multiple myeloma.
19. The method of claim 18 , wherein the multiple myeloma is smoldering multiple myeloma, non-secretory myeloma, osteosclerotic myeloma, plasma cell leukemia, or solitary plasmacytoma.
20. The method of claim 19 , wherein the multiple myeloma is smoldering multiple myeloma.
21. The method of claim 19 , wherein the multiple myeloma is non-secretory myeloma.
22. The method of claim 19 , wherein the multiple myeloma is osteosclerotic myeloma.
23. The method of claim 19 , wherein the multiple myeloma is plasma cell leukemia.
24. The method of claim 19 , wherein the multiple myeloma is solitary plasmacytoma.
25. The method of claim 1 , wherein the compound is
or a pharmaceutically acceptable salt thereof, and wherein the cancer is multiple myeloma.
26. The method of claim 1 , wherein the compound is
or a pharmaceutically acceptable salt thereof, and wherein the cancer is multiple myeloma.
27. The method of claim 1 , wherein the compound is
or a pharmaceutically acceptable salt thereof, and wherein the cancer is multiple myeloma.
28. The method of claim 1 , wherein the compound is
or a pharmaceutically acceptable salt thereof, and wherein the cancer is multiple myeloma.
29. The method of claim 1 , wherein the compound is
or a pharmaceutically acceptable salt thereof, and wherein the cancer is multiple myeloma.
30. The method of claim 1 , wherein the compound is
or a pharmaceutically acceptable salt thereof, and wherein the cancer is multiple myeloma.